SecBot SecBot
SECBOTREPLAY Home › Report › NAMS

NAMS · EC approves obicetrapib

NewAmsterdam Pharma N.V. · PRESS-RELEASE filed Nov 4, 2026 at 07:30 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Nov 4, 2026 at 07:30 ET

NewAmsterdam Pharma reported Q3 2026 net loss of $17.4M, significantly narrower than the $72.0M loss in Q3 2025, driven by a $23.1M non-cash gain on warrant revaluation and $19.2M in revenue from Menarini regulatory milestones. The company received European Commission approval for obicetrapib (Ubeslo and Evlarco), its first regulatory approval worldwide, and initiated the SPINOZA Phase 2b Alzheimer's trial. Cash stood at $643.1M at quarter-end.

  • European Commission granted marketing authorization for Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe FDC) in September 2026, the first regulatory approval of obicetrapib worldwide
  • Net loss of $17.4M in Q3 2026 vs $72.0M in Q3 2025, improvement driven by $23.1M non-cash gain on warrant fair value change and $19.2M in revenue from Menarini regulatory milestones
  • Revenue of $19.2M in Q3 2026 vs $0.3M in Q3 2025, entirely from milestone recognition under the Menarini license agreement
  • Cash, cash equivalents and marketable securities of $643.1M at September 30, 2026, down from $728.9M at December 31, 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access